Please login to the form below

Not currently logged in
Email:
Password:

Oxford Cancer Biomarkers

This page shows the latest Oxford Cancer Biomarkers news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca expands personalised drug partnership with Horizon

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments. AstraZeneca (AZ) has signed a deal with UK genomics company Horizon Discovery to research genetic drug targets for personalised cancer treatments. ... Other recent oncology agreements

Latest news

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    These other deals include the acquisition of cancer specialist Amplimmune and US biotech AlphaCore Pharma; the acquisition of a drug developed by FibroGen for anaemia associated with chronic kidney disease; and ... AZ has also entered research

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    It will allow us to strengthen our arsenal of potential cancer therapies," he added. ... Added to that haul have been collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a $200m licence agreement

  • AZ inks $815m deal for FibroGen anaemia drug AZ inks $815m deal for FibroGen anaemia drug

    Most recently the firm snapped up respiratory specialist Pearl Therapeutics in a deal valued at up to $1.15bn, having previously forged collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford ... Cancer Biomarkers, as well as a

  • AstraZeneca and NGM form diabetes/ obesity partnership AstraZeneca and NGM form diabetes/ obesity partnership

    These deals include the acquisition of Pearl Therapuetics, Omthera Pharmaceuticals and AlphaCore Pharma, as well as collaboration agreements with Moderna Therapuetics and Oxford Cancer Biomarkers.

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    These deals include collaboration agreements with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a licence agreement with Bind Therapeutics and the purchase of US biotechs AlphaCore

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... Critical to that thinking is keeping track of the latest developments in technology and working with companies, such as Oxford Cancer Biomarkers,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics